Viaderma Stock Debt To Equity
| VDRM Stock | USD 0.01 0.0002 2.00% |
Viaderma fundamentals help investors to digest information that contributes to Viaderma's financial success or failures. It also enables traders to predict the movement of Viaderma Pink Sheet. The fundamental analysis module provides a way to measure Viaderma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Viaderma pink sheet.
Viaderma |
Viaderma Company Debt To Equity Analysis
Viaderma's Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Current Viaderma Debt To Equity | 20.90 % |
Most of Viaderma's fundamental indicators, such as Debt To Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Viaderma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
| Competition |
According to the company disclosure, Viaderma has a Debt To Equity of 20.9%. This is 60.96% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The debt to equity for all United States stocks is 57.08% higher than that of the company.
Viaderma Debt To Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Viaderma's direct or indirect competition against its Debt To Equity to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Viaderma could also be used in its relative valuation, which is a method of valuing Viaderma by comparing valuation metrics of similar companies.Viaderma is currently under evaluation in debt to equity category among its peers.
Viaderma Fundamentals
| Return On Asset | -0.91 | |||
| Operating Margin | (13.28) % | |||
| Current Valuation | 6.18 M | |||
| Shares Outstanding | 137.32 K | |||
| Price To Earning | 0.03 X | |||
| Price To Book | 0 X | |||
| Price To Sales | 2.01 X | |||
| Revenue | 44.69 K | |||
| Gross Profit | 37.63 K | |||
| EBITDA | (592.43 K) | |||
| Net Income | (1.52 M) | |||
| Cash And Equivalents | 13.08 K | |||
| Debt To Equity | 20.90 % | |||
| Current Ratio | 0.29 X | |||
| Book Value Per Share | (0) X | |||
| Cash Flow From Operations | (167.36 K) | |||
| Earnings Per Share | 0.16 X | |||
| Beta | -0.42 | |||
| Market Capitalization | 82.27 K | |||
| Total Asset | 426.56 K | |||
| Retained Earnings | (7.38 M) | |||
| Working Capital | (445 K) | |||
| Current Asset | 185 K | |||
| Current Liabilities | 630 K | |||
| Z Score | -28.3 | |||
| Net Asset | 426.56 K |
About Viaderma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Viaderma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Viaderma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Viaderma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectOther Information on Investing in Viaderma Pink Sheet
Viaderma financial ratios help investors to determine whether Viaderma Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Viaderma with respect to the benefits of owning Viaderma security.